Table 1 Current clinical trials of neoantigen-based cancer vaccines
From: Tumor neoantigens: from basic research to clinical applications
Interventions | NCT number | Phase | Enrollment status | Cancer types | Combinations |
|---|---|---|---|---|---|
Neoantigen vaccine | NCT03558945 | I | Recruiting | Pancreatic tumor | None |
Neoantigen vaccine | NCT03359239 | I | Recruiting | Urothelial/bladder cancer | Atezolizumab |
Neoantigen vaccine | NCT03645148 | I | Recruiting | Pancreatic cancer | GM-CSF |
Peptide vaccine | NCT03558945 | II | Not yet recruiting | TNBC | Nab-paclitaxel, Durvalumab |
Peptide vaccine | NCT03929029 | I | Not yet recruiting | Melanoma | Nivolumab, ipilimumab |
Peptide vaccine | NCT03715985 | I | Recruiting | Solid tumors | None |
Peptide vaccine | NCT01970358 | I | Active, not recruiting | Melanoma | None |
Peptide vaccine | NCT03639714 | I/II | Recruiting | Solid tumors | Nivolumab, ipilimumab |
Peptide vaccine | NCT03956056 | I | Not yet recruiting | Pancreatic cancer | Adjuvant chemotherapy |
Peptide vaccine | NCT02287428 | I | Active, not recruiting | Glioblastoma | Radiation therapy |
Peptide vaccine | NCT02950766 | I | Recruiting | Kidney cancer | Ipilimumab |
Peptide vaccine | NCT03219450 | I | Not yet recruiting | Lymphocytic leukemia | Cyclophosphamide |
Peptide vaccine | NCT03422094 | I | Recruiting | Glioblastoma | Nivolumab, ipilimumab |
DC vaccine | NCT03871205 | I | Not yet recruiting | Lung cancer | None |
DC vaccine | NCT02956551 | I | Recruiting | NSCLC | None |
DC vaccine | NCT03674073 | I | Recruiting | Hepatocellular carcinoma | Microwave ablation |
DC vaccine | NCT03300843 | II | Recruiting | Solid tumors | None |
RNA vaccine | NCT03908671 | Not Applicable | Not yet recruiting | Esophageal cancer, NSCLC | None |
RNA vaccine | NCT03480152 | I/II | Recruiting | Solid tumors | None |
RNA vaccine | NCT03468244 | Not Applicable | Recruiting | Solid tumors | None |
DNA vaccine | NCT03532217 | I | Recruiting | Prostate cancer | Nivolumab, Ipilimumab |
DNA vaccine | NCT03122106 | I | Recruiting | Pancreatic cancer | Adjuvant chemotherapy |
DNA vaccine | NCT03199040 | I | Recruiting | TNBC | Durvalumab |